Arkuda Therapeutics
Cambridge
About Arkuda Therapeutics
Arkuda Therapeutics is a biotechnology company leveraging new insights into progranulin and lysosomal biology to develop medicines to change the trajectory of neurodegenerative disease. Arkuda’s lead compounds aim to correct progranulin deficiency and lysosomal dysfunction in GRN-related frontotemporal dementia (FTD-GRN), a genetically-defined subtype of frontotemporal dementia caused by an autosomal dominant mutation in the GRN gene.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $108.0M
- Funding stage: Early Stage Venture
- Last round: Series B (Feb 2022)
- Website: arkudatx.com
- Phone: 857-201-2789
Industries & Categories
Biotechnology, Health Care, Pharmaceutical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/arkuda-therapeutics-79810 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.